Results 191 to 200 of about 15,919 (234)

Pharmacokinetics and Pharmacodynamics of DOAC

2021
Direct oral anticoagulants (DOACs) have become available as an alternative to warfarin anticoagulation in non-valvular atrial fibrillation. The DOACs, dabigatran (a reversible direct thrombin inhibitor) and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban offer fixed dosing, more predictable pharmacokinetics and fewer interactions ...
openaire   +1 more source

DOAC prescribing in people with renal impairment

Drug and Therapeutics Bulletin, 2023
Abstract Overview of: Joy M, Williams J, Emanuel S, et al. Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014–2019). Heart 2022. doi: 10.1136/heartjnl-2022-321377. [Epub ahead of print 9 Sept 2022].
openaire   +2 more sources

Heparins – DOACS – VKA

Phlebologie, 2015
SummaryPatients with cancer are at increased risk of venous thromboembolism (VTE). At the same time they have often an underlying bleeding risk. That can often make decisions surrounding the administration of anticoagulants complicate. Individual risk-benefit calculation is necessary.
openaire   +1 more source

DOAC’s in de huisartsenpraktijk

Praktische Huisartsgeneeskunde, 2017
Het NHG heeft recent een nieuw standpunt anticoagulantia gepubliceerd waarin geen voorkeur meer is voor de cumarinederivaten. DOAC’s worden sindsdien ook vergoed op recept van de huisarts, wat een aantal verwijzingen naar de specialist overbodig zal maken. Wat zijn voor- en nadelen en (contra)indicaties?
openaire   +1 more source

To DOAC or Not to DOAC for Left Ventricular Thrombi—What Is the Dose?

JAMA Cardiology, 2021
Arun, Manmadhan, Jeffrey S, Berger, Tania, Ahuja   +2 more
openaire   +2 more sources

DOAC dose adjustment in renal impairment

Drug and Therapeutics Bulletin, 2020
Abstract Review of: Inohara T, Holmes DN, Pieper K, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart 2020;106:358–364.
openaire   +2 more sources

To DOAC or Not to DOAC for Left Ventricular Thrombi—What Is the Dose?—Reply

JAMA Cardiology, 2021
Austin A, Robinson, Cory R, Trankle, Grayson, Eubanks   +2 more
openaire   +2 more sources

[Towards 'the best DOAC'?]

Nederlands tijdschrift voor geneeskunde, 2020
Direct oral anticoagulants (DOACs) are increasingly being prescribed for stroke prevention in patients with atrial fibrillation or for treating venous thromboembolism. In this short overview, we provide some guidance on possible differences between available DOACs as well as a comparison with traditional treatments using vitamin K antagonists.
Sander, van Doorn, Frans H, Rutten, G J, Geersing   +2 more
openaire   +1 more source

Filtering Out Use of DOACs in Hemodialysis

Annals of Pharmacotherapy, 2017
Published data exploring the best approach to initiating and maintaining anticoagulation in the setting of renal support therapy are scarce, as these patients were excluded in clinical trials. When developing an anticoagulation regimen in this setting, it is important to assess thrombosis risk, identify the unique drivers for thrombosis and bleeding ...
William E, Dager, Jin A, Lee
openaire   +2 more sources

An update on the bleeding risks associated with DOACs

Drug and Therapeutics Bulletin, 2017
The direct oral anticoagulants (DOACs), also referred to as novel (or non-vitamin K antagonist) oral anticoagulants (NOACs), represent a major development in anticoagulation therapy due to their rapid onset of action, predictable dose–response with fixed doses and limited interactions with food and drugs.1,2 However, these agents have been in ...
openaire   +2 more sources